Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“Still an unsolved question in OC: Is there a role for PARPi rechallenge?
The phase II KGOG 3056 / NIRVANA-R trial reports promising activity of niraparib + bevacizumab maintenance in PSROC previously treated with PARPi.
- 6-month PFS rate: 68%
- Median PFS: 11.5 months
- Greater benefit in patients with favorable platinum responsiveness (longer PFI and CR to most recent platinum-based CHT)
- Manageable safety․
Following the OREO study, these data support PARPi rechallenge in carefully selected patients, warranting further investigation in biomarker-driven studies.”
Title: Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Authors: Hyun-Woong Cho, Jeong-Yeol Park, Myong Cheol Lim, Byoung-Gie Kim, Seungbong Han, Min Chul Choi, Jae-Weon Kim, Dae Hoon Jeong, Hae Seo, Jungmin Choi, E. Pujade-Lauraine, Jung-Yun Lee
Read the Full Article.
More posts featuring Giuseppe Caruso․